Heterologous ("nonspecific") and sex-differential effects of vaccines: Epidemiology, clinical trials, and emerging immunologic mechanisms

Clinical Infectious Diseases

Volumn 57, Issue 2, 2013, Pages 283-289

  Flanagan, K L ^a   Van Crevel, R ^b   Curtis, N ^c,d,e   Shann, F ^c,d   Levy, O ^f,g  

^a MONASH UNIVERSITY   (Australia)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

heterologous effects; innate immunity; nonspecific effects; sex differential effects; vaccine

Indexed keywords

BCG VACCINE; MEASLES VACCINE; RETINOL;

ADAPTIVE IMMUNITY; ARTICLE; CLINICAL TRIAL (TOPIC); EPIGENETICS; HETEROLOGOUS EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; INNATE IMMUNITY; LYMPHOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; VITAMIN SUPPLEMENTATION;

HETEROLOGOUS EFFECTS; INNATE IMMUNITY; NONSPECIFIC EFFECTS; SEX-DIFFERENTIAL EFFECTS; VACCINE;

CLINICAL TRIALS AS TOPIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; IMMUNITY, INNATE; MALE; SEX FACTORS; VACCINES;

EID: 84879632085     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit209     Document Type: Article

References (64)

1. Flanagan KL, Klein SL, Skakkebaek NE, et al. Sex differences in the vaccine-specific and non-targeted effects of vaccines. Vaccine 2011; 29:2349-54.
2. Sanchez-Schmitz G, Levy O. Development of newborn and infant vaccines. Sci Transl Med 2011; 3:90ps27.
3. Näslund C. Resultats des experiences de vaccination par le BCG poursuivies dans le Norrbotten (Suède) (Septembre 1927-Décembre 1931). In: Vaccination Preventative de Tuberculose, Rapports et Documents. Paris: Institut Pasteur, 1932.
4. Mayr A. Taking advantage of the positive side-effects of smallpox vaccination. J Vet Med B Infect Dis Vet Public Health 2004; 51:199-201.
5. Shann F. The nonspecific effects of vaccines and the expanded program on immunization. J Infect Dis 2011; 204:182-4.
6. Shann F. Commentary: BCG vaccination halves neonatal mortality. Pediatr Infect Dis J 2012; 31:308-9.
7. Aaby P, Roth A, Ravn H, et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis 2011; 204:245-52.
8. Edmond K, Zaidi A. New approaches to preventing, diagnosing, and treating neonatal sepsis. PLoS Med 2010; 7:e1000213.
9. Ritz N, Dutta B, Donath S, et al. The influence of bacille Calmette- Guerin vaccine strain on the immune response against tuberculosis: A randomized trial. Am J Respir Crit Care Med 2012; 185:213-22.
10. Anderson EJ, Webb EL, Mawa PA, et al. The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in Uganda. Vaccine 2012; 30: 2083-9.
11. Aaby P, Martins CL, Garly M-L, et al. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. BMJ 2010; 341:c6495.
12. Aaby P, Martins CL, Garly M-L, Rodrigues A, Benn CS, Whittle H. The optimal age of measles immunisation in low-income countries: A secondary analysis of the assumptions underlying the current policy. BMJ Open 2012; 2. pii:e000761.
13. Aaby P, Benn C, Nielsen J, Lisse IM, Rodrigues A, Ravn H. Testing the hypothesis that diphtheria-tetanus-pertussis vaccine has negative nonspecific and sex-differential effects on child survival in high-mortality countries. BMJ Open 2012; 2. Available at: http://bmjopen.bmj.com. ezp.lib.unimelb.edu.au/ content/2/3/e000707. Accessed 28 July 2012.
14. Aaby P, Jensen H, Samb B, et al. Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis ofWest African studies. Lancet 2003; 361:2183-8.
15. Geier DA, Geier MR. Serious neurological conditions following pertussis immunization: An analysis of endotoxin levels, the vaccine adverse events reporting system (VAERS) database and literature review. Pediatr Rehabil 2002; 5:177-82.
16. Aaby P, Hedegaard K, Sodemann M, et al. Childhood mortality after oral polio immunisation campaign in Guinea-Bissau. Vaccine 2005; 23:1746-51.
17. Aaby P, Gustafson P, Roth A, et al. Vaccinia scars associated with better survival for adults. An observational study from Guinea-Bissau. Vaccine 2006; 24:5718-25.
18. FawziWW, Chalmers TC, Herrera MG, Mosteller F. Vitamin A supplementation and child mortality. A meta-analysis. JAMA 1993; 269:898-903.
19. Humphrey JH, Agoestina T, Wu L, et al. Impact of neonatal vitamin A supplementation on infant morbidity and mortality. J Pediatr 1996; 128:489-96.
20. Klemm RDW, Labrique AB, Christian P, et al. Newborn vitamin A supplementation reduced infant mortality in rural Bangladesh. Pediatrics 2008; 122:e242-50.
21. Rahmathullah L, Tielsch JM, Thulasiraj RD, et al. Impact of supplementing newborn infants with vitamin A on early infant mortality: community based randomised trial in southern India. BMJ 2003; 327:254.
22. Benn CS, Diness BR, Roth A, et al. Effect of 50,000 IU vitamin A given with BCG vaccine on mortality in infants in Guinea-Bissau: randomised placebo controlled trial. BMJ 2008; 336:1416-20.
23. Benn CS, Fisker AB, Napirna BM, et al. Vitamin A supplementation and BCG vaccination at birth in low birthweight neonates: two by two factorial randomised controlled trial. BMJ 2010; 340:c1101.
24. Humphrey JH, Iliff PJ, Marinda ET, et al. Effects of a single large dose of vitamin A, given during the postpartum period to HIV-positive women and their infants, on child HIV infection, HIV-free survival, and mortality. J Infect Dis 2006; 193:860-71.
25. Malaba LC, Iliff PJ, Nathoo KJ, et al. Effect of postpartum maternal or neonatal vitamin A supplementation on infant mortality among infants born to HIV-negative mothers in Zimbabwe. Am J Clin Nutr 2005; 81:454-60.
26. Gogia S, Sachdev HS. Neonatal vitamin A supplementation for prevention of mortality and morbidity in infancy: systematic review of randomised controlled trials. BMJ 2009; 338:b919.
27. Benn CS, Rodrigues A, Yazdanbakhsh M, et al. The effect of high-dose vitamin A supplementation administered with BCG vaccine at birth may be modified by subsequent DTP vaccination. Vaccine 2009; 27:2891-8.
28. Mora JR, Iwata M, Von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 2008; 8:685-98.
29. Benn CS, Aaby P, Balé C, et al. Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea- Bissau,West Africa. Lancet 1997; 350:101-5.
30. Benn CS, Balde A, George E, et al. Effect of vitamin A supplementation on measles-specific antibody levels in Guinea-Bissau. Lancet 2002; 359:1313-4.
31. Bahl R, Bhandari N, Dube B, et al. Efficacy of early neonatal vitamin A supplementation in reducing mortality during infancy in Ghana, India and Tanzania: study protocol for a randomized controlled trial. Trials 2012; 13:22.
32. Kollmann TR, Levy O, Montgomery RR, Goriely S. Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity 2012; 37:771-83.
33. Fleer A, Krediet TG. Innate immunity: toll-like receptors and some more. A brief history, basic organization and relevance for the human newborn. Neonatology 2007; 92:145-57.
34. Belderbos ME, Levy O, Meyaard L, Bont L. Plasma-mediated immune suppression: A neonatal perspective. Pediatr Allergy Immunol 2013; 24:102-13.
35. Kollmann TR, Crabtree J, Rein-Weston A, et al. Neonatal innate TLRmediated responses are distinct from those of adults. J Immunol 2009; 183:7150-60.
36. Levy O, Goriely S, Kollmann TR. Immune response to vaccine adjuvants during the first year of life [Epub ahead of print]. Vaccine 2012; doi:10.1016/j.vaccine.2012.10.016.
37. Demirjian A, Levy O. Safety and efficacy of neonatal vaccination. Eur J Immunol 2009; 39:36-46.
38. Ota MOC, Vekemans J, Schlegel-Haueter SE, et al. Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J Immunol 2002; 168:919-25.
39. Sanchez-Schmitz G, Stevens C, Baecher-Allan C, Levy O. A novel human neonatal tissue construct (NTC) models age-specific immune responses to bacille Calmette-Guérin (BCG) vaccine. In: Abstracts from the 99th Annual Meeting of The American Society of Immunologists (Boston). J Immunol 2012; 188:166.27.
40. Wynn JL, Scumpia PO, Winfield RD, et al. Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists. Blood 2008; 112:1750-8.
41. Philbin VJ, Dowling DJ, Gallington LC, et al. Imidazoquinoline Tolllike receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. J Allergy Clin Immunol 2012; 130:195-204.e9.
42. Lisciandro JG, Prescott SL, Nadal-Sims MG, et al. Ontogeny of Tolllike and NOD-like receptor-mediated innate immune responses in Papua New Guinean infants. PLoS One 2012; 7:e36793.
43. Burl S, Townend J, Njie-Jobe J, et al. Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants. PLoS One 2011; 6:e18185.
44. Netea MG, Quintin J, Van der Meer JWM. Trained immunity: A memory for innate host defense. Cell Host Microbe 2011; 9:355-61.
45. Sun JC, Beilke JN, Lanier LL. Immune memory redefined: characterizing the longevity of natural killer cells. Immunol Rev 2010; 236:83-94.
46. Sun JC, Lopez-Verges S, Kim CC, DeRisi JL, Lanier LL. NK cells and immune 'memory.' J Immunol 2011; 186:1891-7.
47. Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A 2012; 109:17537-42.
48. Lee GR, Kim ST, Spilianakis CG, Fields PE, Flavell RA. T helper cell differentiation: regulation by cis elements and epigenetics. Immunity 2006; 24:369-79.
49. Sanders VM. Epigenetic regulation of Th1 and Th2 cell development. Brain Behav Immun 2006; 20:317-24.
50. Martino DJ, Prescott SL. Silent mysteries: epigenetic paradigms could hold the key to conquering the epidemic of allergy and immune disease. Allergy 2010; 65:7-15.
51. Martino DJ, Tulic MK, Gordon L, et al. Evidence for age-related and individual- specific changes in DNA methylation profile of mononuclear cells during early immune development in humans. Epigenetics 2011; 6:1085-94.
52. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 2010; 10:338-49.
53. Klein SL. Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases. Bioessays 2012; 34:1050-9.
54. Klein SL. Immune cells have sex and so should journal articles. Endocrinology 2012; 153:2544-50.
55. Pennell LM, Galligan CL, Fish EN. Sex affects immunity. J Autoimmun 2012; 38:J282-91.
56. Selin LK, Wlodarczyk MF, Kraft AR, et al. Heterologous immunity: immunopathology, autoimmunity and protection during viral infections. Autoimmunity 2011; 44:328-47.
57. Ruckwardt TJ, Malloy AMW, Gostick E, et al. Neonatal CD8 T-cell hierarchy is distinct from adults and is influenced by intrinsic T cell properties in respiratory syncytial virus infected mice. PLoS Pathog 2011; 7: e1002377.
58. Chen AT, Cornberg M, Gras S, et al. Loss of anti-viral immunity by infection with a virus encoding a cross-reactive pathogenic epitope. PLoS Pathog 2012; 8:e1002633.
59. Clute SC, Naumov YN, Watkin LB, et al. Broad cross-reactive TCR repertoires recognizing dissimilar Epstein-Barr and influenza A virus epitopes. J Immunol 2010; 185:6753-64.
60. Van Riet E, Adegnika AA, Retra K, et al. Cellular and humoral responses to influenza in Gabonese children living in rural and semi-urban areas. J Infect Dis 2007; 196:1671-8.
61. Van Riet E, Retra K, Adegnika AA, et al. Cellular and humoral responses to tetanus vaccination in Gabonese children. Vaccine 2008; 26:3690-5.
62. Lalor MK, Floyd S, Gorak-Stolinska P, et al. BCG vaccination induces different cytokine profiles following infant BCG vaccination in the UK and Malawi. J Infect Dis 2011; 204:1075-85.
63. Dockrell HM, Smith SG, Lalor MK. Variability between countries in cytokine responses to BCG vaccination: what impact might this have on protection? Expert Rev Vaccines 2012; 11:121-4.
64. Blimkie D, Fortuno ES 3rd, Yan H, et al. Variables to be controlled in the assessment of blood innate immune responses to Toll-like receptor stimulation. J Immunol Methods 2011; 366:89-99.